Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Supratentorial diffuse low-grade gliomas present a slow macroscopic tumor growth that can be quantified through the measurement of their velocity of diametric expansion. We assessed whether spontaneous velocity of diametric expansion can predict long-term outcomes as a categorical variable and as a continuous predictor. METHODS: A total of 407 adult patients with newly diagnosed supratentorial diffuse low-grade gliomas in adults were studied. RESULTS: The mean spontaneous velocity of diametric expansion before first-line treatment was 5.8 ± 6.3 mm/year. During the follow-up (mean, 86.5 ± 59.4 months), 209 patients presented a malignant transformation, and 87 died. The malignant progression-free survival and the overall survival were significantly longer in cases of slow velocity of diametric expansion (median, 103 and 249 months, respectively) than in cases of fast velocity of diametric expansion (median, 35 and 91 months, respectively; P < .001). In multivariate analyses, spontaneous velocity of diametric expansion as a categorical variable (<4, ≥4 and <8, ≥8 and <12, ≥12 mm/year) was an independent prognostic factor for malignant progression-free survival (P < .001; hazard ratio, 3.87; 95% confidence interval [CI], 2.67-5.52) and for overall survival (P < .001; hazard ratio, 4.62; 95% CI, 2.58-7.97). Velocity of diametric expansion was also an independent prognostic factor for overall survival as a continuous predictor, showing a linear relationship between overall survival and spontaneous velocity of diametric expansion (hazard ratio, 1.09 per one unit increase; 95% CI, 1.06-1.12; P < .001). CONCLUSIONS: Independent of the molecular status, the spontaneous velocity of diametric expansion allows the identification of rapidly growing diffuse low-grade gliomas (at higher risk of worsened evolution) during the pretherapeutic period and without delaying treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“VDE, the rate of change in tumor diameter over time, is an independent predictor of outcome in LGGs [43,44,45].”
From BPC 157 Therapy of Myotendinous Junction Injury in Rats (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Erratum to: The 2007 WHO classification of tumours of the central nervous system
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-156115 · Cited by 4,442
— Tumors of the Central Nervous System
(2013) · Pediatric Radiotherapy Planning and Treatment · doi:10.1201/b14554-7 · Cited by 1,751
GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME
Sanai, N., & Berger, M. S. (2008) · Neurosurgery · doi:10.1227/01.neu.0000318159.21731.cf · Cited by 1,328 · cited 7×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
BackgroundInfluentialSelf-citationRole of extent of resection in the long-term outcome of low-grade hemispheric gliomas
Smith, J. S., Chang, E. F., Lamborn, K. R., Chang, S. M., Prados, M. D., Cha, S., Tihan, T., VandenBerg, S., McDermott, M. W., & Berger, M. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9337 · Cited by 1,283 · cited 9×
“Diffuse low-grade gliomas affect young adults3 and are characterized by a slow tumor growth,4 even in the silent period,5 and a transformation to a higher grade of malignancy, leading to neurological disability and, ultimately, to death.6,7 Early maximal safe resection while preserving eloquent brain areas with use of…”
InfluentialPrognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955 · cited 1×
“2 mm over a 3-month period) should be considered as high-risk patients together with those without IDH mutation and those with known risk factors according to Pignatti and Chang scoring systems.(20,27) Because these LGGs share outcomes similar to those of malignant gliomas, treatment modalities should be selected acco…”
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
Soffietti, R., Baumert, B. G., Bello, L., Von Deimling, A., Duffau, H., Frénay, M., Grisold, W., Grant, R., Graus, F., Hoang‐Xuan, K., et al. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03151.x · Cited by 505 · cited 1×
“Early maximal safe resection while preserving eloquent brain areas with use of perioperative functional monitoring is currently considered as the first-line treatment option.(3,8) Indeed, there is a growing trend that the extent of resection is a significant prognostic factor for malignant progression-free survival an…”
Self-citationContinuous growth of mean tumor diameter in a subset of grade II gliomas
Mandonnet, E., Delattre, J., Tanguy, M., Swanson, K. R., Carpentier, A. F., Duffau, H., Cornu, P., Van Effenterre, R., Alvord, E. C., & Capelle, L. (2003) · Annals of Neurology · doi:10.1002/ana.10528 · Cited by 493 · cited 1×
“It has previously been reported that LGGs demonstrate a spontaneous velocity of diametric expansion of 4 mm/year before and after surgical resection.(4,14) Of interest, velocity of diametric expansion changes after oncological treatment can predict outcomes in response to chemotherapy and radiotherapy.”
Self-citationPallud, J., Mandonnet, E., Duffau, H., Kujas, M., Guillevin, R., Galanaud, D., Taillandier, L., & Capelle, L. (2006) · Annals of Neurology · doi:10.1002/ana.20946 · Cited by 250 · cited 8×
“This pioneer study addressed only the prognostic significance on overall survival of velocity of diametric expansion as a categorical variable in a subset of 143 LGGs.6 It appears to be logical that the higher the velocity of diametric expansion is, the worse the outcomes are.”
InfluentialSelf-citationSwanson, K. R., Rockne, R. C., Claridge, J., Chaplain, M. A., Alvord, E. C., & Anderson, A. R. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1399 · Cited by 236 · cited 1×
“Accordingly, cell density in such tumors may not be high enough to generate hypoxic foci triggering neoangiogenesis and may lead to a LGG appearance on pathological examination.(28) Indeed, pathological findings do not exhibit significant differences in the spontaneous velocity of diametric expansion.”
Cited by
Items 101–174 of 174
Castello, A., Riva, M., Fernandes, B., Bello, L., & Lopci, E. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001202 · Cited by 7
Ullah, M. A., Tabassum, T., Farzana, M., Moin, A. T., Zohora, U. S., & Rahman, M. S. (2022) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2022.103922 · Cited by 6
Yao, S., Yang, R., Du, C., Jiang, C., Wang, Y., Peng, C., & Bai, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1089139 · Cited by 6
Is the volume of low-grade glioma measurable and is it clinically relevant?
Chamberlain, M. C. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou119 · Cited by 6
Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors
Rudà, R., Bruno, F., Pellerino, A., Pronello, E., & Soffietti, R. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516617 · Cited by 5
Morrow, K. D., Sloan, A. E., Olson, J. J., & Ormond, D. R. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04838-5 · Cited by 6
Challenges in starting an awake craniotomy project in a low resource public health system.
Albuquerque, L., Diógenes, G. S., & Pessoa, F. C. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.12.006 · Cited by 3
Duffau, H. (2025) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01402-6 · Cited by 7
“Remarkably, glioma growth rate is an independent prognostic factor of survival, because tumors progressing faster have more aggressive intrinsic behavior [20], regardless of their molecular profile, particularly IDH status [21].”
Self-citationConsiderations for a surgical RCT for diffuse low-grade glioma: a survey
Mansouri, A., Brar, K., & Cusimano, M. D. (2019) · Neuro-Oncology Practice · doi:10.1093/nop/npz058 · Cited by 5
Current State of Health Economic Analyses for Low-Grade Glioma Management: A Systematic Review
Tuohy, K. J., Fernandez, A., Hamidi, N., Padmanaban, V., & Mansouri, A. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.05.112 · Cited by 6
Matek, D., Pevec, D., Boban-Blagaic, A., & Sikiric, P. (2025) · Biomedicines · doi:10.3390/biomedicines13010201 · Cited by 4
Treatment Options for IDH-Mutant Malignant Gliomas
Swensen, S., Figuracion, K. C., Venur, V. A., Emerson, S., Tseng, Y. D., Lo, S. S.-M., Ermoian, R. P., & Halasz, L. M. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01280-7 · Cited by 4
Deverdun, J., Clain, G., Verdier, M., Duffau, H., van Dokkum, L. E. H., de Champfleur, N. M., Meriadec, J., Carriere, M., Darlix, A., & Bars, E. L. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf256 · Cited by 5
Self-citationDiffusion Imaging with MR Tractography for Brain Tumor Surgery
Bizzi, A. (2014) · Medical radiology · doi:10.1007/978-3-662-45123-6_7 · Cited by 4
Rauch, P., Aichholzer, M., Serra, C., Zanier, O., Staartjes, V. E., Böhm, P., Seyer, G., Wagner, H., Manakov, I., Sonnberger, M., et al. (2024) · Neurosurgical FOCUS · doi:10.3171/2023.11.focus23685 · Cited by 3
Natural History and Spontaneous Prognostic Factors
Rudà, R., Bertero, L., & Soffietti, R. (2013) · Springer eBooks · doi:10.1007/978-1-4471-2213-5_18 · Cited by 4
Darlix, A., Bady, P., Deverdun, J., Bars, E. L., Coget, A., Meriadec, J., Carriere, M., Duffau, H., & Hegi, M. E. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf296 · Cited by 2
Self-citationQin, X., Chen, Z., Wu, L., & Ding, R. (2024) · Medicine · doi:10.1097/md.0000000000039316 · Cited by 3
“[3,4] Therefore, it is imperative to excavate neoteric biomarkers for LGG therapy.”
BackgroundDTI Analysis of the Peritumoral Zone of Diffuse Low-grade Gliomas in Progressing Patients
Chiche, D., Taillandier, L., Blonski, M., Planel, S., Obara, T., Anxionnat, R., & Rech, F. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.10.111 · Cited by 2
Self-citationXie, R., Huang, H., Cai, Q., Lu, J.-Y., Chen, T., Xie, K., Chen, J., & Chen, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1445558 · Cited by 3
Duffau, H. (2025) · Neurosurgery · doi:10.1227/neu.0000000000003760 · Cited by 4
Self-citationIs a prospective trial necessary to suggest a clinical relevance?
Pallud, J., & Duffau, H. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou156 · Cited by 2
Self-citationFast-growing oligodendrogliomas are aggressive tumors—the real life biomarker?
Geurts, M., & van den Bent, M. J. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa097 · Cited by 2
Tumor Volume Growth as Surrogate Endpoint in IDH-mt Glioma—Response
Bhatia, A., Moreno, R., Reiner, A. S., Nandakumar, S., Walch, H. S., Malani, R., Panageas, K. S., Mellinghoff, I. K., Bale, T., & Young, R. J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3603 · Cited by 2
Pallud, J. (2020) · Neuro-Oncology Practice · doi:10.1093/nop/npaa027 · Cited by 1
Self-citationRisk factors for early progression of diffuse low-grade glioma in adults
Wang, L., Li, X., Chen, T., Zhang, C., Shi, J., Feng, H., & Li, F. (2022) · Chinese Neurosurgical Journal · doi:10.1186/s41016-022-00295-z · Cited by 4
“The risk of malignant transformation in DLGG is highly dependent on tumor volume and growth rate [11].”
BackgroundManagement of Recurrent Gliomas: An Update of Strategies and Treatment Options
Cofano, F., Morello, A., Rizzo, F., Marco, R. D., & Garbossa, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-81850-9_18 · Cited by 1
Ge, Z., Jin, G., Wang, H., Wang, S., Fei, X., Li, S., Zhang, L., Jiang, X., & Zhang, Y. (2025) · Surgical Oncology · doi:10.1016/j.suronc.2025.102327 · Cited by 1
Han, J., Zhao, B., Yue, M., Hou, M., Han, X., Sun, T., Yun, R., Dai, Y., Jia, J., Wang, H., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003921 · Cited by 1
Wu, J., & Wang, N. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01401-4 · Cited by 2
“Untreated diffuse low-grade gliomas may show continuous growth even while scans appear deceptively quiet, and both pretherapeutic growth rates and velocity of spontaneous expansion have been linked to out - come and malignant transformation risk [15–17].”
Almairac, F., Herbet, G., Moritz‐Gasser, S., de Champfleur, N. M., & Duffau, H. (2013) · Neurochirurgie · doi:10.1016/j.neuchi.2013.10.048 · Cited by 2
“91 mois, p < 0,001) [89].”
BackgroundSelf-citationNew Individualized and Dynamic Therapeutic Strategies in DLGG
Duffau, H., & Taillandier, L. (2017) · Springer eBooks · doi:10.1007/978-3-319-55466-2_28 · Cited by 1
Self-citationHu, X., Ma, Y., Xia, Y., & Liu, B. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23947 · Cited by 2
“However, recent studies have revealed that LGG continues to grow at an average rate of 4 – 5 mm per year [3].”
BackgroundSurgery for Diffuse Low-Grade Gliomas (DLGG) Oncological Outcomes
Duffau, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-55466-2_23 · Cited by 1
Self-citationDiffuse low grade gliomas - how it is to diagnose and treat effectively?
Reguli, Š., Cvek, J., & Lipina, R. (2019) · Onkologie · doi:10.36290/xon.2019.025 · Cited by 1
Diffusion Imaging with MR Tractography for Brain Tumor Surgery
Bizzi, A. (2021) · Medical radiology · doi:10.1007/978-3-030-83343-5_7 · Cited by 1
Liu, Y., Fan, Z., Li, S., Liu, X., Jiang, T., Wang, Y., & Wang, L. (2022) · Annals of Translational Medicine · doi:10.21037/atm-21-3998 · Cited by 1
“In contrast, IDH1 variations are considered to have no significant influence on tumor growth (8,9,17).”
InfluentialDetection of local growth patterns in longitudinally imaged low-grade gliomasPreprint
Gui, C., Kai, J., KHAN, A. R., Lau, J. C., & Megyesi, J. F. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.24.488099 · Cited by 1
Conduite à tenir devant un gliome diffus de bas grade
Mandonnet, E. (2014) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2014.07.002 · Cited by 1
Self-citationÉvaluation et rééducation de la mémoire de travail après chirurgie éveillée de gliomes infiltrants
Bismuth, B., & Chabot, A. (2015) · HAL · Cited by 1
Duffau, H. (2017) · Springer eBooks · doi:10.1007/978-3-319-55466-2_1
Self-citationClinical Presentation in Diffuse Low-Grade Gliomas
Smits, A., & Jakola, A. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-55466-2_11 · Cited by 1
Pregnancy and Diffuse Low-Grade Gliomas
Peeters, S., & Pallud, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-55466-2_30
Self-citationGravidanza e gliomi diffusi di basso grado
Roux, A., & Pallud, J. (2018) · EMC - Neurologia · doi:10.1016/s1634-7072(17)87847-8
Self-citationSurgical Resection Techniques of Central Area Gliomas
Sabel, M., Rapp, M., Smuga, M., & Kamp, M. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-95918-4_21
Surgical management of 1p/19q co-deleted oligodendrogliomas WHO grade II and III
Thon, N., Kreth, F.-W., & Tonn, J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813158-9.00018-9
Neoformazioni intracraniche: gliomi di grado II
Darlix, A., Rigau, V., & Duffau, H. (2020) · EMC - Neurologia · doi:10.1016/s1634-7072(20)44227-8
Self-citationWang, Y., Huo, L., & Ke, Z. (2021) · Research Square · doi:10.21203/rs.3.rs-139589/v1
“Moreover, DLGG can grow at an average rate of 4– 5 mm per year, resulting in a slow malignant transformation which will lead to death of patients(5).”
BackgroundComparative Parameters of Occult and Multiple Brain Tumors In Human: The Implication for TherapyPreprint
Saganuwan, S. A. (2021) · Research Square · doi:10.21203/rs.3.rs-628825/v1
Low-Grade Gliomas: A Single-Institute Experience
Nasreen, S., Najmi, A. M., Andleeb, A., Fatima, K., Sofi, M. A., & Banday, S. Z. (2022) · Journal of Radiation and Cancer Research · doi:10.4103/jrcr.jrcr_42_21
Natural History and Spontaneous Prognostic Factors
Rudà, R., Pellerino, A., & Soffietti, R. (2017) · Springer eBooks · doi:10.1007/978-3-319-55466-2_17
Almairac, F., Herbet, G., Moritz‐Gasser, S., de Champfleur, N. M., & Duffau, H. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.01.189 · Cited by 1
Self-citationGrau, S., & Goldbrunner, R. (2017) · Springer eBooks · doi:10.1007/978-3-662-48694-8_23
Maimaiti, A., Liu, Y., Abulaiti, A., Wang, X., Feng, Z., Wang, J., Mijiti, M., Turhon, M., Alimu, N., Wang, Y., et al. (2023) · Journal of Molecular Neuroscience · doi:10.1007/s12031-023-02116-z · Cited by 1
Zhang, F., Wang, X., Zhang, X., Waheed, S., Zhong, R., Armato, U., Wu, J., Chiarini, A., Prà, I. D., Zhang, C., et al. (2023) · ONCOLOGIE · doi:10.1515/oncologie-2022-1002
Travelling waves for low-grade glioma growth and response to a chemotherapy model
Bartłomiejczyk, A., Bodnar, M., Bogdańska, M., & Piotrowska, M. J. (2023) · International Journal of Applied Mathematics and Computer Science · doi:10.34768/amcs-2023-0041
“This agrees with the speed of LGGs’ progression reported by Pallud et al. (2013; 2012) and Adenis et al. (2021).”
ResultLow-Grade Glioma in the Differential Diagnosis of Limbic Encephalitis
Villanueva-Castro, E., Reséndiz, R. H., Muñuzuri-Camacho, M. A., Thomas, D. J. C., Jiménez-Quintero, L. D. A., Díaz, B. C., Reyes-Moreno, I., Gutiérrez-Aceves, G. A., Guerrero-Juárez, V., Ramírez‐Bermúdez, J., et al. (2025) · Cureus · doi:10.7759/cureus.83899
“However, grade 2 gliomas are slow-growing neoplasms with distinct phases: asymptomatic, clinical onset, anaplastic degeneration, and refractory/progression [4].”
The Role of Surgery Along the Diffuse Low-Grade Glioma Timeline: Insights into Surgical Paradigms
Ius, T., Bertolotti, C., Agosti, E., Bagatto, D., & Panciani, P. P. (2025) · Springer eBooks · doi:10.1007/978-3-031-81850-9_7
The Neuro-Oncological Balance in the Modern Era
Armocida, D., Corvino, S., Santoro, A., Pesce, A., & Frati, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-81850-9_10
Darlix, A., Bady, P., Deverdun, J., Bars, E. L., Coget, A., Meriadec, J., Carriere, M., Duffau, H., & Hegi, M. E. (2025) · medRxiv · doi:10.1101/2025.10.21.25338454
Self-citationde Albuquerque, L. A., & Almeida, J. P. (2025) · Springer eBooks · doi:10.1007/978-3-031-95119-0_11
Chen, H., Liang, W., Li, Z., Bian, C., Wang, H., Luo, S. J., You, X., Feng, W., & Liang, L. (2025) · BMC Cancer · doi:10.1186/s12885-025-15406-z
“Recent studies have shown that LGG shortens survival [29], which means that defining prognostic markers is an urgent need.”
Lopes, T. L. M., Balsells, M. D., Cavalcante, M. A. O. D. M., de Queiroz, A. G. D., Filho, H. F. L., de Almeida, M. V., de Sousa, Y. G., Matos, L. E. O., Polverini, A. D., de Albuquerque, L. A. F., et al. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05430-9
Self-citationUn modèle de l'évolution des gliomes diffus de bas grade sous chimiothérapie
Abdallah, M. B. (2016) · theses.fr (ABES) · doi:10.70675/58a76823z4bf2z4316z899cz1973a873ee0e · Cited by 1
Zouaoui, S. (2015) · theses.fr (ABES) · doi:10.70675/4d41c5aczc8d1z45d0zadb1zecad4111ce94
Characterization of cellular heterogeneity in Diffuse Low Grade Glioma
Augustus, M. (2020) · theses.fr (ABES) · doi:10.70675/037c23a4z44ddz4bb7z999ezb0c178c35170
Blonski, M. (2021) · theses.fr (ABES) · doi:10.70675/449078ddz0ec7z44c5z80f4zfcf91836c6d4
Self-citation中洲, 敏., 中洲庸子, Nakasu, S., & Nakasu, Y. (n.d.) · Institutional Repositories DataBase (IRDB)
Mandonnet, E. (2026) · Acta Neurochirurgica · doi:10.1007/s00701-026-06944-x
“…of FLAIR hypersig-nal at the level of the anterior perforated substance residue, but the slight increase at the level of the superior temporal gyrus strongest prognostic factor of these tumors [6, 7], hence a posteriori verification of balance between the two groups would have been welcome.”
Self-citationDarlix, A., Teruel, E., Trinquet, A., Bars, E. L., Duffau, H., Ng, S., Rigau, V., Duc, M.-S., Carriere, M., & Deverdun, J. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag183
Self-citationAtli, B., Wartha, M., Gmeiner, M., Aichholzer, M., Weis, S., Vorhauer, D., Wagner, H., Hauer, T., Serra, C., Böhm, P., et al. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05803-0
Hervey‐Jumper, S. L., & Berger, M. S. (2014) · Springer eBooks · doi:10.1007/978-3-319-10693-9_1
Metadata
- Authors
- Pallud, J., Blonski, M., Mandonnet, E., Audureau, E., Fontaine, D., Sanai, N., Bauchet, L., Peruzzi, P., Frénay, M., Colin, P., Guillevin, R., Bernier, V., Baron, M.-H., Guyotat, J., Duffau, H., Taillandier, L., & Capelle, L.
- Affiliations
- Barrow Neurological Institute (US)
- Corresponding author
- Pallud, Johan
- ORCID
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-07
- Volume
- 15
- Issue
- 5
- Pages
- 595-606
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC3635513
- OpenAlex
- W2160995760
- Cited by
- 173
- References
- 33
- Citations by year
- 2026: 5 · 2025: 18 · 2024: 8 · 2023: 12 · 2022: 14 · 2021: 13 · 2020: 17 · 2019: 15 · 2018: 16 · 2017: 24 · 2016: 5 · 2015: 11 · 2014: 11 · 2013: 4
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuro-Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Keywords
- diffuse low-grade glioma, tumor growth rate, malignant transformation, prognostic factors, progression-free survival, overall survival, supratentorial glioma, adult glioma
- MeSH terms
- Adolescent, Adult, Aged, Brain Neoplasms, Female, Follow-Up Studies, Glioma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Survival Rate, Tumor Burden, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.